---
title: "AI hardware sector declines in the afternoon, GongJin hits the limit down"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/224525429.md"
description: "AI hardware sector declined in the afternoon, GongJin and Hite Control hit the limit down, while Bochuang Technology, Taicheng Light, Luxiao Technology, Zhongji Xuchuang, and NewEase also followed suit"
datetime: "2025-01-10T05:19:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/224525429.md)
  - [en](https://longbridge.com/en/news/224525429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/224525429.md)
generator: "portal-rs"
---

# AI hardware sector declines in the afternoon, GongJin hits the limit down

AI hardware sector declined in the afternoon, GongJin and Hite Control hit the limit down, while Bochuang Technology, Taicheng Light, Luxiao Technology, Zhongji Xuchuang, and Xinyi Sheng also followed the decline

### Related Stocks

- [002184.CN](https://longbridge.com/en/quote/002184.CN.md)
- [603118.CN](https://longbridge.com/en/quote/603118.CN.md)
- [002617.CN](https://longbridge.com/en/quote/002617.CN.md)
- [300308.CN](https://longbridge.com/en/quote/300308.CN.md)
- [300502.CN](https://longbridge.com/en/quote/300502.CN.md)
- [300548.CN](https://longbridge.com/en/quote/300548.CN.md)
- [300570.CN](https://longbridge.com/en/quote/300570.CN.md)

## Related News & Research

- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)
- [CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications](https://longbridge.com/en/news/297638498.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)
- [Xinhua Pharma unit Xincat’s azithromycin tablets pass China generic consistency evaluation](https://longbridge.com/en/news/297485179.md)
- [Kalshi issues first lifetime ban for Republican politician over insider bets](https://longbridge.com/en/news/297684078.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**